HistoSonics is a commercial-stage medtech company advancing the Edison® System, a novel non-invasive sonic beam therapy based on histotripsy. Since receiving FDA De Novo grant for the non-invasive destruction of liver tumors in 2023, the company has progressed beyond initial market entry into commercial expansion, reimbursement momentum, and ongoing clinical and pipeline development. In addition to its current liver tumor indication, HistoSonics is pursuing future indications across multiple ap…
Our engineering team is dedicated to building robust, scalable solutions that solve real-world problems. You will work alongside senior developers to architect and deploy high-quality code. We emphasize continuous learning, peer code reviews, and staying ahead of the curve with emerging technologies.
Enter your email to receive daily job updates—for free. Plus, get an exclusive career resource instantly when you subscribe!
Get weekly career tips and new job alerts.